全文获取类型
收费全文 | 149篇 |
免费 | 12篇 |
专业分类
基础医学 | 5篇 |
口腔科学 | 3篇 |
临床医学 | 4篇 |
内科学 | 4篇 |
皮肤病学 | 9篇 |
神经病学 | 2篇 |
特种医学 | 2篇 |
外科学 | 33篇 |
综合类 | 2篇 |
预防医学 | 14篇 |
眼科学 | 2篇 |
药学 | 13篇 |
肿瘤学 | 68篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 6篇 |
2020年 | 2篇 |
2019年 | 7篇 |
2018年 | 8篇 |
2017年 | 7篇 |
2016年 | 3篇 |
2015年 | 2篇 |
2014年 | 8篇 |
2013年 | 12篇 |
2012年 | 13篇 |
2011年 | 7篇 |
2010年 | 4篇 |
2009年 | 2篇 |
2008年 | 13篇 |
2007年 | 8篇 |
2006年 | 5篇 |
2005年 | 11篇 |
2004年 | 8篇 |
2003年 | 7篇 |
2002年 | 9篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1983年 | 2篇 |
1979年 | 1篇 |
排序方式: 共有161条查询结果,搜索用时 15 毫秒
81.
Nils Kroeger Toni K. Choueiri Jae-Lyn Lee Georg A. Bjarnason Jennifer J. Knox Mary J. MacKenzie Lori Wood Sandy Srinivas Ulka N. Vaishamayan Sun-Young Rha Sumanta K. Pal Takeshi Yuasa Frede Donskov Neeraj Agarwal Min-Han Tan Aristotelis Bamias Christian K. Kollmannsberger Scott A. North Brian I. Rini Daniel Y.C. Heng 《European urology》2014
Background
A subset of primarily localized renal cell carcinoma (RCC) patients will experience disease recurrence ≥5 yr after initial nephrectomy.Objective
To characterize the clinical outcome of patients with late recurrence beyond 5 yr.Design, setting, and participants
Patients with metastatic RCC (mRCC) treated with targeted therapy were retrospectively characterized according to time to relapse. Relapse was defined as the diagnosis of recurrent metastatic disease >3 mo after initial curative-intent nephrectomy. Patients with synchronous metastatic disease at presentation were excluded. Patients were classified as early relapsers (ERs) if they recurred within 5 yr; late relapsers (LRs) recurred after 5 yr.Outcome measurements and statistical analysis
Demographics were compared with the Student t test, the chi-square test, or the Fisher exact test. The survival time was estimated with the Kaplan-Meier method, and associations with survival outcome were assessed with univariable and multivariable Cox regression analyses.Results and limitations
Among 1210 mRCC patients treated with targeted therapy after surgery for localized disease, 897 (74%) relapsed within the first 5 yr and 313 (26%) (range: 5–35 yr) after 5 yr. LRs presented with younger age (p < 0.0001), fewer with sarcomatoid features (p < 0.0001), more clear cell histology (p = 0.001), and lower Fuhrman grade (p < 0.0001). Overall objective response rates to targeted therapy were better in LRs versus ERs (31.8% vs 26.5%; p = 0.004). LRs had significantly longer progression-free survival (10.7 mo vs 8.5 mo; p = 0.005) and overall survival (OS; 34.0 mo vs 27.4 mo; p = 0.004). The study is limited by its retrospective design, noncentralized imaging and pathology review, missing information on metastatectomy, and nonstandardized follow-up protocols.Conclusions
A quarter of patients who eventually developed metastatic disease and were treated with targeted therapy relapsed over 5 yr from initial nephrectomy. LRs have more favorable prognostic features and consequently better treatment response and OS. 相似文献82.
Ethan M. Basch Mark Scholz Johann S. de Bono Nicholas Vogelzang Paul de Souza Gavin Marx Ulka Vaishampayan Saby George James K. Schwarz Emmanuel S. Antonarakis Joseph M. OSullivan Arash Rezazadeh Kalebasty Kim N. Chi Robert Dreicer Thomas E. Hutson Amylou C. Dueck Antonia V. Bennett Erica Dayan Howard I. Scher 《European urology》2019,75(6):929-937
BackgroundBone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) are associated with debilitating pain and functional compromise.ObjectiveTo compare pain palliation as the primary endpoint for cabozantinib versus mitoxantrone-prednisone in men with mCRPC and symptomatic bone metastases using patient-reported outcome measures.Design, setting, and participantsA randomized, double-blind phase 3 trial (COMET-2; NCT01522443) in men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment with docetaxel and either abiraterone or enzalutamide.InterventionCabozantinib 60 mg once daily orally versus mitoxantrone 12 mg/m2 every 3 wk plus prednisone 5 mg twice daily orally.Outcome measurements and statistical analysisThe primary endpoint was pain response at week 6 confirmed at week 12 (≥30% decrease from baseline in patient-reported average daily worst pain score via the Brief Pain Inventory without increased narcotic use). The planned sample size was 246 to achieve ≥90% power.Results and limitationsEnrollment was terminated early because cabozantinib did not demonstrate a survival benefit in the companion COMET-1 trial. At study closure, 119 participants were randomized (cabozantinib: N = 61; mitoxantrone-prednisone: N = 58). Complete pain and narcotic use data were available at baseline, week 6, and week 12 for 73/106 (69%) patients. There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a ?2% difference (95% confidence interval: ?16% to 11%, p = 0.8). Barriers to accrual included pretreatment requirements for a washout period of prior anticancer therapy and a narcotic optimization period to maximize analgesic dosing.ConclusionsCabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases. Future pain-palliation trials should incorporate briefer timelines from enrollment to treatment initiation.Patient summaryCabozantinib was not better than mitoxantrone-prednisone for pain relief in patients with castration-resistant prostate cancer and debilitating pain from bone metastases. 相似文献
83.
84.
85.
The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century 总被引:2,自引:0,他引:2
High-risk prostate cancer is a heterogeneous group that includes patients with clinically locally advanced stage disease at diagnosis. Unlike overt locally advanced disease, prediction of risk in clinically localized disease at an individual patient level, is not always easy or accurate with present knowledge. Gleason score, pretreatment prostate specific antigen (PSA), and stage (capsular invasion, seminal vesicle and nodal involvement) are the universally recognized criteria used to define risk. Overall, this group of patients have a greater than 50% risk of relapse. Historically, local treatment modalities with radical prostatectomy or radiation therapy constituted the mainstay of therapy in the majority of localized prostate cancer patients. However, the primary cause of failure and disease mortality stems from the development of systemic metastases. As we continue to witness stage migration towards earlier stage disease (presumably PSA related) and mortality reduction, devising better strategies for cure is a must. Recently completed randomized trials indicate a benefit from the use of hormonal therapy in patients with locally advanced prostate cancer treated with radiation therapy or node positive patients, post radical prostatectomy. While hormone-based combined modality trials have consistently shown improvements in local and systemic disease control, only two of these demonstrated improvements in overall survival. The palliative benefit of chemotherapy in hormone refractory disease and the promising response rates with newer agents has evoked interest in the use of chemotherapy in high-risk prostate cancer in the adjuvant and neoadjuvant settings. Several phase II and III trials are ongoing. Novel avenues of therapy such as tyrosine kinase inhibitors, gene therapy and angiogenesis inhibitors incorporated in a multimodality treatment strategy are likely to impact the course of this disease in the future. 相似文献
86.
A case of dermoid cyst with intracranial extension in a 10-year-old boy is reported. Intracranial extension of dermoid is not very common. 相似文献
87.
88.
Lycopene and soy isoflavones in the treatment of prostate cancer 总被引:2,自引:0,他引:2
Vaishampayan U Hussain M Banerjee M Seren S Sarkar FH Fontana J Forman JD Cher ML Powell I Pontes JE Kucuk O 《Nutrition and cancer》2007,59(1):1-7
Dietary intake of lycopene and soy has been associated with a lower risk of prostate cancer. In vitro studies with lycopene and genistein, a soy isoflavone, have shown induction of apoptosis and inhibition of cell growth in androgen-sensitive (LNCaP) and androgen-independent (PC3 and VeCaP) prostate cancer cell lines. In a previous Phase II clinical trial in prostate cancer patients, we observed prostate-specific antigen (PSA) stabilization with soy isoflavone intake. In this Phase II clinical trial, we investigated the efficacy of lycopene alone or in combination with soy isoflavones on serum PSA levels in men with prostate cancer. To be eligible for the study, men with prostate cancer had to have rising serum PSA following local therapy or while on hormone therapy. Study population included 71 eligible patients who had 3 successive rising PSA levels or a minimum PSA of 10 ng/ml at 2 successive evaluations prior to starting therapy. Subjects were randomly assigned to receive a tomato extract capsule containing 15 mg of lycopene alone (n = 38) or together with a capsule containing 40 mg of a soy isoflavone mixture (n = 33) twice daily orally for a maximum of 6 mo. One patient on the lycopene arm did not receive therapy due to his inability to ingest the study pill. There was no decline in serum PSA in either group qualifying for a partial or complete response. However, 35 of 37 (95%) evaluable patients in the lycopene group and 22 of 33 (67%) evaluable patients in the lycopene plus soy isoflavone group achieved stable disease described as stabilization in serum PSA level. The data suggest that lycopene and soy isoflavones have activity in prostate cancer patients with PSA relapse disease and may delay progression of both hormone-refractory and hormone-sensitive prostate cancer. However, there may not be an additive effect between the 2 compounds when taken together. Future studies are warranted to further investigate the efficacy of lycopene and soy isoflavones in prostate cancer as well as the mechanism of potential negative interaction between them. 相似文献
89.
Michael R. Harrison MD Brian A. Costello MD Nrupen A. Bhavsar PhD Ulka Vaishampayan MD Sumanta K. Pal MD Yousef Zakharia MD Heather S. L. Jim PhD Mayer N. Fishman MD Ana M. Molina MD Christos E. Kyriakopoulos MD Che-Kai Tsao MD Leonard J. Appleman MD Benjamin A. Gartrell MD Arif Hussain MD Walter M. Stadler MD Neeraj Agarwal MD Russell K. Pachynski MD Thomas E. Hutson DO Hans J. Hammers MD Christopher W. Ryan MD Brant A. Inman MD Jack Mardekian PhD Azah Borham PharmD Daniel J. George MD 《Cancer》2021,127(13):2204-2212
90.
Jun Xu Xiangdong Cui Jiehua Li Panagiotis Koutakis Iraklis Pipinos Edith Tzeng Alex Chen Ulka Sachdev 《Journal of vascular surgery》2018,67(3):910-921